Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
Candel Therapeutics announced that an abstract featuring extended data from the Phase 3 trial of aglatimagene besadenovec was accepted for presentation at the ASTRO 2026 Annual Meeting. The poster presentation will focus on quantitative digital pathology defining immune activation in localized prostate cancer.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.